Take a closer look at bone histology of TYMLOS

As a safety measure, a subset of patients in the TYMLOS (n=36) and placebo (n=35) groups underwent bone biopsies after 12 to 18 months of treatment1

Bone sample representing a T-score of -1.6

In both groups, qualitative and quantitative* histology showed normal bone microarchitecture
and no evidence of woven bone, marrow fibrosis, or mineralization defects1

Fifty-five biopsies were adequate for quantitative histomorphometry assessment in the TYMLOS (n=27) and placebo (n=28) groups.1

View the clinical results of the 18-month pivotal study

Reference: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    08/17.   ABLSC-US-01042

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 08/17.
ABLSC-US-01042